Pharmaceutical-Grade Levodopa IR Pellets for Immediate-Release Oral Formulations
Levodopa IR Pellets are multiparticulate pharmaceutical formulations designed for immediate-release oral dosage applications. Levodopa (L-Dopa) is identified by CAS Number 59-92-7, molecular formula C₉H₁₁NO₄, and molecular weight 197.19 g/mol.
The SDP pellet product portfolio lists Levodopa IR Pellets at 50% strength, providing a defined active-loading option for pharmaceutical formulation development.
The immediate-release pellet format provides a multiparticulate platform intended for rapid release of the active ingredient according to the finished formulation specification. Pellet composition, active loading, particle characteristics and manufacturing parameters influence the final release performance.
Levodopa, also known as L-Dopa, has the molecular formula C₉H₁₁NO₄, molecular weight 197.19 g/mol, and CAS Number 59-92-7. PubChem identifies it as the L-enantiomer of 3,4-dihydroxyphenylalanine.
For Levodopa IR Pellets, the 50% value represents active ingredient loading in the finished pellet formulation. It should not be confused with the purity assay of the Levodopa raw material.
Levodopa IR Pellets — 50%
The 50% strength is listed for Levodopa IR Pellets in the referenced pharmaceutical pellet product portfolio.
Levodopa IR Pellets can be considered for:
Levodopa IR Pellets can be supplied in suitable bulk packaging according to customer requirements. Strength, batch quantity, packaging configuration and applicable technical documentation can be specified according to the intended pharmaceutical formulation.
| Parameter | Specification |
|---|---|
| Appearance | white to off-white crystalline powder |
| Identification | IR & HPLC compliant |
| Assay (HPLC) | 95.0% – 105.0% |
| Loss on Drying | NMT 2.0% |
| Residue on Ignition | NMT 0.5% |
| Individual Impurity | NMT 0.5% |
| Total Impurities | NMT 1.0% |
| Water Content | NMT 2.0% |